ONCODESIGN announced the strengthening of its patent portfolio concerning RIPK2 (Receptor-interacting serine/threonine-protein kinase 2) inhibitor macrocyclic compounds, as well as the successful completion of the preclinical toxicological evaluation of its ODS-101 drug candidate. The RIPK2 kinase inhibitors developed by Oncodesign have substantial therapeutic potential in inflammatory intestinal diseases aiming for a specific targeted action, a market estimated at close to USD 7 billion in 2023, an increase of +17% compared with 2018 (global figures). The medical need for an orally administered immune response regulator in inflammatory bowel disease is substantial, and complements current therapeutic options based on immunosuppressors and monoclonal antibodies.